NuCana (NCNA) shares soared 164% amid heavy trading after the company said Saturday that a combination of NUC-7738 and pembrolizumab led to prolonged progression-free survival in a phase 2 trial for patients with metastatic melanoma.
More than 50.1 million shares traded intraday compared with a daily average of about 138,000.
Nuvalent (NUVL) said Saturday that data from the ongoing parallel phase 1/2 trials of zidesamtinib and NVL-655 to treat non-small cell lung cancer showed "favorable tolerability."
Shares climbed 23%, with intraday trading volume at over 1.9 million compared with a daily average of about 344,000.
Zentalis Pharmaceuticals (ZNTL) said the US Food and Drug Administration lifted a partial clinical hold on studies of azenosertib, the company's novel and orally bioavailable inhibitor for advanced solid tumors.
Shares advanced 20% as intraday trading volume rose to 41.4 million versus the stock's daily average of about 1.49 million.
Price: 6.71, Change: +4.17, Percent Change: +164.09
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。